Adults with Rheumatoid Arthritis
Etanercept is indicated to reduce signs and symptoms and inhibit the structural damage progression in patients with moderate to severe active rheumatoid arthritis.
Etanercept may be started in combination with methotrexate or as monotherapy. Etanercept is indicated for the treatment of moderate to severe active rheumatoid arthritis when the response to one or more DMARDs (disease-modifying antirheumatic drugs) has been inadequate.
Adults with Psoriatic Arthritis
Etanercept is indicated to inhibit structural damage and reduce signs and symptoms in patients with psoriatic arthritis.
Etanercept may be used with or without methotrexate.
Axial Spondyloarthritis
Adults with Ankylosing Spondylitis
Etanercept is indicated to reduce signs and symptoms in patients with active ankylosing spondylitis.
Adults with Non-Radiographic Axial Spondyloarthritis
Etanercept is indicated for the treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation, as demonstrated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging findings, who have had an inadequate response to or are intolerant to conventional therapy.
Adults with Plaque Psoriasis
Etanercept is indicated for the treatment of adult patients (18 years or older) with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Biologic; fusion protein antibody.
Anti–TNF (tumor necrosis factor).
Immunology.
Sale by prescription only.
Bionovis is a pioneer in the production and commercialization of biological and biosimilar medicines.
Our pursuit of scientific innovations and highly complex medicines aims to build a healthier Brazil — and a healthier world — for everyone.
© 2025 Bionovis. Companhia Brasileira de Biotecnologia Farmacêutica.